tiprankstipranks
Altamira Therapeutics (CYTO)
NASDAQ:CYTO
US Market
Holding CYTO?
Track your performance easily

Altamira Therapeutics (CYTO) Stock Price & Analysis

598 Followers

CYTO Stock Chart & Stats


Financials

Annual

Ownership Overview

0.06%2.68%97.26%
Insiders
2.68% Other Institutional Investors
97.26% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

CYTO FAQ

What was Altamira Therapeutics’s price range in the past 12 months?
Altamira Therapeutics lowest stock price was $0.40 and its highest was $17.21 in the past 12 months.
    What is Altamira Therapeutics’s market cap?
    Currently, no data Available
    When is Altamira Therapeutics’s upcoming earnings report date?
    Altamira Therapeutics’s upcoming earnings report date is Apr 09, 2025 which is in 137 days.
      How were Altamira Therapeutics’s earnings last quarter?
      Altamira Therapeutics released its earnings results on Sep 24, 2024. The company reported -$2.022 earnings per share for the quarter, beating the consensus estimate of -$2.425 by $0.402.
        Is Altamira Therapeutics overvalued?
        According to Wall Street analysts Altamira Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Altamira Therapeutics pay dividends?
          Altamira Therapeutics does not currently pay dividends.
          What is Altamira Therapeutics’s EPS estimate?
          Altamira Therapeutics’s EPS estimate is -$0.58.
            How many shares outstanding does Altamira Therapeutics have?
            Altamira Therapeutics has 3,778,524 shares outstanding.
              What happened to Altamira Therapeutics’s price movement after its last earnings report?
              Altamira Therapeutics reported an EPS of -$2.022 in its last earnings report, beating expectations of -$2.425. Following the earnings report the stock price went up 4.478%.
                Which hedge fund is a major shareholder of Altamira Therapeutics?
                Currently, no hedge funds are holding shares in CYTO
                ---

                Altamira Therapeutics Stock Smart Score

                10
                Unlock Smart Score
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Technicals

                SMA
                Negative
                20 days / 200 days
                Momentum
                -94.06%
                12-Months-Change

                Fundamentals

                Return on Equity
                Trailing 12-Months
                Asset Growth
                16.36%
                Trailing 12-Months

                Company Description

                Altamira Therapeutics

                Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The firm focuses on the development of intranasal betahistine for the treatment of vertigo and for the prevention of antipsychotic-induced weight gain and somnolence. It also includes other programs under development such as Keyzilen, for the treatment of acute inner ear tinnitus; and Sonsuvi, for the treatment of acute inner ear hearing loss. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.
                ---

                CYTO Earnings Call

                Q2 2024
                0:00 / 0:00
                ---
                Similar Stocks
                Company
                Price & Change
                Follow
                NovaBay Pharma
                SELLAS Life Sciences Group
                TFF Pharmaceuticals
                Amicus
                Popular Stocks
                ---
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis